spawns
- CG Oncology (CGON) shares climbed ~31% on Friday after the corporate stated {that a} late-stage trial for its lead asset, cretostimogene grenadenorepvec, is now anticipated to generate topline knowledge in H1 2026, practically a yr sooner than its prior plan.
